

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
08 December 2022 (08.12.2022)



(10) International Publication Number
WO 2022/256449 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) A61P 35/00 (2006.01)
C07K 14/05 (2006.01)

(21) International Application Number:
PCT/US2022/031836

(22) International Filing Date:
01 June 2022 (01.06.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/202,211 01 June 2021 (01.06.2021) US
63/263,809 09 November 2021 (09.11.2021) US
63/362,594 06 April 2022 (06.04.2022) US

(71) Applicant: **TRIUMVIRA IMMUNOLOGICS USA, INC.** [US/US]; 9433 Bee Cave Road, Building I, Suite 240, Austin, Texas 78733 (US).

(72) Inventors: **BADER, Andreas**; 9433 Bee Cave Road, Building I, Suite 240, Austin, Texas 78733 (US). **HELSEN, Christopher W.**; 9433 Bee Cave Road, Building I, Suite


240, Austin, Texas 78733 (US). **IP, Philbert**; 9433 Bee Cave Road, Building I, Suite 240, Austin, Texas 78733 (US). **BENATAR, Tania**; 9433 Bee Cave Road, Building I, Suite 240, Austin, Texas 78733 (US). **WANG, Ling**; 333 Louis Drive, Mississauga, Ontario L5B1Z2 (CA).

(74) Agent: **POULOS, Sabrina D.**; 100 Northern Avenue, IP DOCKETING DEPT./7TH FL, Boston, Massachusetts 02210 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: CLAUDIN 18.2 T CELL-ANTIGEN COUPLERS AND USES THEREOF

Figure 1



(57) Abstract: Claudin 18.2 T cell antigen couplers (TACs) polypeptides having (i) an antigen-binding domain that binds Claudin 18.2, (ii) an antigen-binding domain that binds a protein associated with a TCR complex, and (iii) a T cell receptor signaling domain polypeptide are provided. Nucleic acids encoding the claudin 18/2 TACs are also provided.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*